CME Credits:
Credits for Specialists: This event is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification program of the Royal College of Physicians and Surgeons of Canada, and approved by Queen’s University.

Learning Objectives:
− To identify and address, through clinical trial and translational research, the disease burden associated with genitourinary malignancies in Canada.
− To identify clinical trial research opportunities within the Canadian Cancer Trials Group.
− To integrate current knowledge regarding therapeutics and tumour biology in trial concept development and conduct.
− To integrate and apply new clinical trial methodologies in the Canadian Cancer Trials Group research agenda.
− To provide a learning environment to all investigators and a mentoring environment supportive to new investigators.

7:00 am  Non-Prostate Priority setting breakout  D. Heng/ K. Sridhar
8:00 am  Prostate Priority setting breakout  S. Hotte/T. Niazi
9:00 am  Coffee break
9:15 am  Main Meeting - Welcome and Chairs Report  K. Chi/ N. Fleshner
9:30 am  CCTG Approved Trials

PR.21 PLUDO (Prostate Lutetium/Docetaxel):  K. Chi/F. Saad/F. Benard
A Randomized Phase II Study of 177Lu-PSMA-617 vs Docetaxel in Patients with Metastatic Castration-Resistant Prostate Cancer and PSMA-Positive Disease

PR.22 Darolutamide Augments Standard Therapy  C. Sweeney/T. Niazi
for Localized High-Risk Cancer of the Prostate (DSAL-HiCaP)

10:00 am  CCTG Led Open Trials

IND.223: A Phase II Study of Palbociclib, A CDK4/6 Inhibitor, in Patients with Metastatic Castration-Resistant Prostate Cancer  K. Chi

IND.232: A Phase II Study of Durvalumab (Medi4736) with or without Tremelimumab in Patients with Metastatic Castration Resistant Prostate Cancer  S. Hotte

IND.234: Prostate Cancer Biomarker Enrichment and Treatment Selection (PC_BETS) Study - Master Screening Protocol  K. Chi

BL.13 A Randomized Phase II Trial Assessing Trimodality Therapy With Or Without Adjuvant Durvalumab To Treat Patients With
Muscle-Invasive Bladder Cancer

PM.1: Prostate Cancer Biomarker Enrichment and Treatment Selection (PC_BETS) Study - Master Screening Protocol K. Chi

PR.19: A Randomized Phase II trial Evaluating Treatment Outcome, Acute and Long-term toxicity of High Dose Rate Brachytherapy (HDRB) and Low Dose Rate Brachytherapy (LDRB) as Monotherapy in Localized Prostate Cancer. G. Morton/ E. Vigneault

PR.20: A Randomized Phase III Study of Local Ablative Therapy for Hormone Sensitive Oligometastatic Prostate Cancer (PLATON) P. Cheung/T. Niazi

10:50 am CCTG Intergroup Open Trials

BLC.4 (SWOG S1605): Phase II Trial of Atezolizumab (NSC #783606) in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer. W. Kassouf

PNC.1 InPACT: International Penile Advanced Cancer Trial J. Crook

REC.3/PAPMET A Randomized, Phase II Efficacy Assessment of Multiple MET Kinase Inhibitors Cabozantinib, Crizotinib and Savolitinib versus Sunitinib in Metastatic Papillary Renal Carcinoma D. Heng

REC.4/PROSPER RCC A Phase 3 Randomized Study Comparing PERioperative Nivolumab vs. Observation in Patients with Localized Renal Cell Carcinoma Undergoing Nephrectomy A. Kapoor

11:10 am CCTG Intergroup Closed Trials

PR.17/ANZUP 1304- ENZAMET Phase III testosterone suppression with or without Enzalutamide in first line metastatic prostate cancer S. North

PR.13/RADICALS/MRC PR.10 Radiotherapy and Androgen Deprivation In Combination After Local Surgery C. Catton

BLC.1/SWOG S1011 Phase III Surgical Trial to Evaluate the Benefit of a Standard versus an Extended Pelvic Lymphadenectomy Performed at the Time Of Radical Cystectomy For Muscle Invasive Urothelial Cancer W. Kassouf

PRC.3/CALGB 90203 Neoadjuvant Docetaxel plus Androgen Deprivation prior to RP v.s. RP only K.Chi

PRC.4/Alliance A031201 Phase III Enzalutamide + Abiraterone in castration resistant metastatic prostate cancer K.Chi

11:30 am New Trial Proposals

S1909 A Phase III Randomized Trial of Erlilubin with or without Gemcitabine vs. Standard of Care Metastatic Urothelial Carcinoma refractory to, or ineligible for, anti PD1/PDL1 Therapy K. Sridhar

POUT2 (ICR-UK) B. Eigl

12:00 pm LUNCH

1:30 pm OPEN CUOG/CURC TRIALS N. Fleshner

2:00 pm GU Trial Development Group – review of activities and feedback K. Chi

2:15 pm GU correlative sciences report D. Berman

2:30 pm Report from priority setting breakout sessions D. Heng/ K.Sridhar/ S. Hotte/ T. Niazi

3:30 pm – 4:00 pm GUDSC Executive Committee CLOSED